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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to a 
combination of Lactobacillus delbrueckii subsp. bulgaricus AY/CSL 
(LMG P-17224) and Streptococcus thermophilus 9Y/CSL (LMG P-17225) 
and “beneficial modulation of intestinal microflora” pursuant to Article 14 
of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from CSL - Centro Sperimentale del Latte S.p.A., submitted pursuant to Article 14 of 
Regulation (EC) No 1924/2006 via the Competent Authority of Italy, the Panel on Dietetic Products, Nutrition 
and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to a 
combination of Lactobacillus delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and Streptococcus 
thermophilus 9Y/CSL (LMG P-17225) and “beneficial modulation of intestinal microflora”. The scope of the 
application was proposed to fall under a health claim referring to children’s development and health. The food 
constituent that is the subject of the health claim, a combination of L. delbrueckii subsp. bulgaricus AY/CSL 
(LMG P-17224) and S. thermophilus 9Y/CSL (LMG P-17225), has not been sufficiently characterised. The 
claimed effect is “beneficial modulation of the intestinal microflora”. The target population, as proposed by the 
applicant, is children from 3 months to 14 years old. No evidence has been provided by the applicant to establish 
that the claimed effect, “beneficial modulation of the intestinal microflora”, is a beneficial physiological effect. 
The Panel concludes that a cause and effect relationship has not been established between the consumption of the 
food constituent, the combination of L. delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and 
S. thermophilus 9Y/CSL (LMG P-17225), and a beneficial physiological effect related to “beneficial modulation 
of the intestinal microflora”. © European Food Safety Authority, 2011 
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SUMMARY 
Following an application from CSL - Centro Sperimentale del Latte S.p.A., submitted pursuant to 
Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Italy, the Panel on 
Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific 
substantiation of a health claim related to a combination of Lactobacillus delbrueckii subsp. 
bulgaricus AY/CSL (LMG P-17224) and Streptococcus thermophilus 9Y/CSL (LMG P-17225) and 
“beneficial modulation of intestinal microflora”. 
The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
The food constituent that is the subject of the health claim is a combination of L. delbrueckii subsp. 
bulgaricus AY/CSL (LMG P-17224) and S. thermophilus 9Y/CSL (LMG P-17225). No complete data 
on the identification and characterisation of the strains L. delbrueckii subsp. bulgaricus AY/CSL 
(LMG P-17224) and S. thermophilus 9Y/CSL (LMG P-17225) were provided in the application or 
after the Panel’s request to the applicant for supplementary information. The Panel considers that the 
food constituent, the combination of L. delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and S. 
thermophilus 9Y/CSL (LMG P-17225), which is the subject of the health claim, has not been 
sufficiently characterised. 
The claimed effect is “beneficial modulation of the intestinal microflora”. The target population, as 
proposed by the applicant, is children from 3 months to 14 years old.  
According to Regulation (EC) No 1924/2006, the use of health claims shall only be permitted if the 
food/constituent, for which the claim is made, has been shown to have a beneficial physiological 
effect. Based on current scientific knowledge, it is not possible to define the exact 
numbers/proportions of the different microbial groups which constitute a “beneficial” or “normal” 
intestinal microbiota. Increasing the number of any group of microorganisms, including lactobacilli 
and/or bifidobacteria, is not considered in itself a beneficial physiological effect. Thus, the applicant 
was requested to provide the rationale regarding the extent to which the claimed effect is a beneficial 
physiological effect. No reply was received from the applicant to the Panel’s request for 
supplementary information. The Panel considers that no evidence has been provided by the applicant 
to establish that the claimed effect, “beneficial modulation of the intestinal microflora", is a beneficial 
physiological effect. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of the food constituent, the combination of L. delbrueckii 
subsp. bulgaricus AY/CSL (LMG P-17224) and S. thermophilus 9Y/CSL (LMG P-17225), and a 
beneficial physiological effect related to “beneficial modulation of the intestinal microflora”.  
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of 
permitted claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 07/04/2008. 
 The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
 During the check for completeness5 of the application, the applicant was requested to provide 
missing information on 03/06/2008 and subsequently on 20/07/2009 and 06/08/2009. 
 The applicant provided the missing information on 10/07/2009, and subsequently on 
29/07/2009,07/08/2009 and 31/08/2009. 
 The scientific evaluation procedure started on 15/09/2009. 
 On 12/11/2009, the NDA Panel Working Group on Claims agreed on a list of questions for 
the applicant to provide additional information to accompany the application and on 
16/11/2009 EFSA requested the applicant to provide this additional information.  
 No response to the NDA Panel List of Questions was received from the applicant, even 
subsequent to EFSA reminders on 03/03/2010 and 18/04/2011. 
 During its meeting of 30/06/2011, the NDA Panel, having evaluated the available data 
submitted, adopted an opinion on the scientific substantiation of a health claim related to a 
combination of L. delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and 
S. thermophilus 9Y/CSL (LMG P-17225) and “beneficial modulation of intestinal 
microflora”. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to a combination of L. delbrueckii 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
5  In accordance with: EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. Scientific and technical 
guidance for the preparation and presentation of an application for authorisation of a health claim (revision 1). EFSA 
Journal, 9(5):2170, 36 pp. 
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subsp. bulgaricus AY/CSL (LMG P-17224) and S. thermophilus 9Y/CSL (LMG P-17225) and 
“beneficial modulation of intestinal microflora”. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of a combination of L. delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and S. thermophilus 
9Y/CSL (LMG P-17225), a positive assessment of its safety, nor a decision on whether the 
combination of L. delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and S.thermophilus 
9Y/CSL (LMG P-17225) is, or is not, classified as a foodstuff. It should be noted that such an 
assessment is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: CSL - Centro Sperimentale del Latte S.p.A., Strada per Merlino, 3 - 
26839 Zelo Buon Persico (LO), Italy. 
The application includes proprietary data. 
Food/constituent as stated by the applicant 
Mix of Lactobacillus delbrueckii subsp. bulgaricus strain AY/CSL (LMG P-17224) and 
Streptococcus thermophilus strain 9Y/CSL (LMG P-17225). 
Health relationship as claimed by the applicant 
According to the applicant, both strains survive gastro-intestinal transit, colonise the intestine, and 
balance the intestinal flora.  
S. thermophilus is an oxygen scavenger: so creates anaerobic conditions that enhance the growth and 
survival of strict anaerobes, like bifidobacteria, in the intestine. Furthermore, the ability of L. 
bulgaricus to adhere to the mucosal surfaces is related to various probiotic health effects, and it is 
regarded as a prerequisite for stimulation of the immune system and for antagonistic activity against 
enteropathogens. The acidifying activities and the production of H2O2 in situ by Lactobacillus 
delbrueckii subsp. bulgaricus and Streptococcus thermophilus can lead to a growth-inhibiting pH for 
most putrefactive and pathogenic bacteria in the intestine, like clostridia and Enterobacteriaceae. 
Wording of the health claim as proposed by the applicant 
“Maintaining the gut health by normalizing the intestinal flora”. 
Specific conditions of use as proposed by the applicant 
Cell concentration of the food constituent (in the form of freeze-dried viable cells / starter culture): 
L. delbrueckii subsp. bulgaricus strain AY/CSL: at least 5 x 10
8
 CFU/g 
S. thermophilus strain 9Y/CSL: at least 5 x 10
8
 CFU/g 
Target population: Children from 3 months to 14 years old.  
Cow’s milk allergic infants should avoid eating cow’s milk yoghurt. 
ASSESSMENT 
1. Characterisation of the food/constituent and relevance of the claimed effect to human 
health 
The food constituent that is the subject of health claim is a combination of Lactobacillus delbrueckii 
subsp. bulgaricus AY/CSL (LMG P-17224) and Streptococcus thermophilus 9Y/CSL 
(LMG P-17225).  
The applicant provided phenotypic data and some genotypic data to confirm the identity at species 
level of the strains that are the subject of the claim. The applicant indicated that the strains were 
identified at species level by species-specific PCR, 16S rRNA gene sequencing and RAPD-PCR, but 
only data on species-specific PCR were provided. Such data are insufficient to confirm species 
identity. Data on strain characterisation (genetic typing) were not provided.  
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The applicant was requested to provide supplementary information about the characterisation of the 
strains, which are the subject of the claim, and about the identity of the strains used in the studies 
provided for substantiation of the claim. No reply was received from the applicant.  
The strains were deposited in the Belgian Coordinate Collections of Microorganisms (BCCM) and the 
following culture collection numbers for each strain were provided: LMG P-17224 for L. delbrueckii 
subsp. bulgaricus and LMG P-17225 for S. thermophilus 9Y/CSL. The BCCM is an International 
Depositary Authority under the Budapest Treaty and accepts bacterial cultures as patent deposits. 
These deposits have restricted access and are not catalogued. 
The Panel notes that no complete data on the identification and characterisation of the strains 
L. delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) and S. thermophilus 9Y/CSL 
(LMG P-17225) were provided in the application or after the Panel’s request to the applicant for 
supplementary information. The Panel considers that the combination of L. delbrueckii subsp. 
bulgaricus AY/CSL (LMG P-17224) and S. thermophilus 9Y/CSL (LMG P-17225), which is the 
subject of the health claim, has not been sufficiently characterised. 
The claimed effect is “beneficial modulation of the intestinal microflora”. The target population, as 
proposed by the applicant, is children from 3 months to 14 years old.  
According to Regulation (EC) No 1924/2006, the use of health claims shall only be permitted if the 
food/constituent, for which the claim is made, has been shown to have a beneficial physiological 
effect. Based on current scientific knowledge, it is not possible to define the exact 
numbers/proportions of the different microbial groups which constitute a “beneficial” or “normal” 
intestinal microbiota. Increasing the number of any group of microorganisms, including lactobacilli 
and/or bifidobacteria, is not considered in itself a beneficial physiological effect.  
The applicant was requested to provide the rationale regarding the extent to which the claimed effect 
is a beneficial physiological effect. No reply was received from the applicant to the Panel’s request 
for supplementary information. 
In the studies provided by the applicant (Dellaglio, 2009, unpublished; Bianchi Salvadori et al., 1967; 
Salvadori et al., 1973; Bianchi Salvadori et al. 1978), outcome measures included faecal counts of 
lactobacilli, bifidobacteria and enterobacteria (but characterisation of the pathogenicity of 
enterobacteria was not provided), stool pH, and survival of the strains after gastro-intestinal transit. 
The Panel notes that changes in these outcome measures are not considered beneficial physiological 
effects per se.  
The Panel considers that no evidence has been provided by the applicant to establish that the claimed 
effect, “beneficial modulation of the intestinal microflora”, is a beneficial physiological effect. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food constituent, the combination of L. delbrueckii subsp. bulgaricus AY/CSL 
(LMG P-17224) and S. thermophilus 9Y/CSL (LMG P-17225), and a beneficial physiological effect 
related to “beneficial modulation of the intestinal microflora”. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, the combination of L. delbrueckii subsp. bulgaricus AY/CSL 
(LMG P-17224) and S. thermophilus 9Y/CSL (LMG P-17225), which is the subject of the 
health claim, has not been sufficiently characterised. 
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 The claimed effect is “beneficial modulation of the intestinal microflora”. The target 
population, as proposed by the applicant, is children from 3 months to 14 years old. 
 No evidence has been provided to establish that the claimed effect, “beneficial modulation of 
the intestinal microflora”, is a beneficial physiological effect.  
 A cause and effect relationship has not been established between the consumption of the food 
constituent, the combination of L. delbrueckii subsp. bulgaricus AY/CSL (LMG P-17224) 
and S. thermophilus 9Y/CSL (LMG P-17225), and a beneficial physiological effect related to 
“beneficial modulation of the intestinal microflora”. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on a combination of Lactobacillus delbrueckii subsp. bulgaricus AY/CSL 
(LMG P-17224) and Streptococcus thermophilus 9Y/CSL (LMG P-17225) and “beneficial 
modulation of the intestinal microflora” pursuant to Article 14 of Regulation (EC) No 1924/2006 
(Claim serial No: 0143_IT). 29 July 2009. Submitted by CSL - Centro Sperimentale del Latte S.p.A. 
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rRNA  Ribosomal RNA 
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PCR  Polymerase Chain Reaction 
RAPD  Randomly Amplified Polymorphic DNA 
 
